ImmunityBio (IBRX) vs Kymera Therapeutics (KYMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmunityBio (IBRX) has outperformed Kymera Therapeutics (KYMR) over the past year, gaining 290.0% versus a gain of 90.4%. Over five years, KYMR leads with a +89.4% price change compared with +4.8% for IBRX. ImmunityBio is the larger company by market cap ($10.45 billion vs $8.94 billion), about 1.2 times the size.
ImmunityBio converts more of its revenue into profit, with a net margin of -310.2% versus -794.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | KYMR |
|---|---|---|
| Share price | $9.86 | $108.65 |
| Market cap | $10.45B | $8.94B |
| 1-day change | +1.13% | +0.28% |
| YTD return | +392.42% | +39.25% |
| 1-year return | +290.00% | +90.35% |
| 5-year return | +4.84% | +89.42% |
| EPS (TTM) | $-0.96 | $-3.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $113.29M | $39.21M |
| Revenue growth (YoY) | +668.31% | -16.70% |
| Net income (latest FY) | $-351.40M | $-311.35M |
| Gross margin | 99.34% | 0.00% |
| Operating margin | -226.00% | -891.07% |
| Net margin | -310.18% | -794.04% |
| 52-week high | $12.43 | $130.05 |
| 52-week low | $1.95 | $55.26 |
| Distance from 52-week high | -20.68% | -16.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.31% | +28.23% |
| Average volume | 10.29M | 698.42K |
| Shares outstanding | 1.06B | 82.26M |
| Employees | 684 | 273 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed KYMR by 199.6 percentage points over the past year.
- ImmunityBio is more profitable, keeping -310.2 cents of every revenue dollar as net income versus -794.0 cents for Kymera Therapeutics.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs -16.70%).
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 273 employees
IBRX vs KYMR FAQ
Which is bigger, ImmunityBio or Kymera Therapeutics?
ImmunityBio (IBRX) is larger, with a market capitalization of $10.45B compared with $8.94B for Kymera Therapeutics (KYMR).
Which stock has performed better over the past year, IBRX or KYMR?
IBRX returned +290.00% over the past 12 months, compared with +90.35% for KYMR (price return, excluding dividends). Past performance does not predict future results.
Are ImmunityBio and Kymera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.